Clinical relevance of statins: Instituting treatment early in acute coronary syndrome patients

Atherosclerosis Supplements

Volumn 2, Issue 1, 2001, Pages 15-19

  Thompson, Peter L ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

LAMIL; PACT; PAIS

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COLESTYRAMINE; EPTIFIBATIDE; FIBRINOLYTIC AGENT; GATIFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; HYPOCHOLESTEROLEMIC AGENT;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0035260814     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(00)00005-2     Document Type: Conference Paper

References (22)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335:1996;1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 339:1998;1349-1357.
4. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. 333:1995;1301-1307.
5. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279:1998;1615-1622.
6. Lacoste L., Lam J.Y., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
7. Dangas G., Smith D.A., Unger A.H., et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Haemost. 83:2000;688-692.
8. Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med. 340:1999;115-1126.
9. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation. 98:1998;839-844.
10. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. The cholesterol and recurrent events (CARE) investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:1999;230-235.
11. Crisby M., Shah P.K., Yano J., et al. Pravastatin pre-treatment increases collagen content, and decreases lipid content, inflammation, matrix metalloproteinase s and cell death in human carotid plaques favouring lesion stability. Circulation. 100:(Suppl. I):1999;1-469. Abstract.
12. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl. J. Med. 332:1995;488-493.
13. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronarysyndromes. The RECIFE (Reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 99:1999;3227-3233.
14. Mostaza J.M., Gomez M.V., Gallardo F., et al. Cholesterol reduction improves myocardial perfusion abnormalities in patientswith coronary artery disease and average cholesterol levels. J. Am. Coll. Cardiol. 35:2000;76-82.
15. Kesteloot H., Claeys G., Blanckaert N., Lesaffre E. Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Acta Cardiol. 2:1997;107-116.
16. den Hartog F.R., Verhengt F.W.A. Early HMG CoA reductase inhibition in acute coronary syndromes: preliminary data from the Pravastatin in Acute Ischaemic Syndromes study. Eur. Heart J. 19:1997;402. Abstract.
17. Kayikcioglu M., Turkoglu C., Kultursay H., Harum H., Can L. Combined use of pravastatin and thrombolytic agents in acute myocardial infarction. Pravastatin Turkish trial. Circulation. 100:(Suppl. I):1999;1-303.
18. Arntz H.R., Wunderlich W., Schnitzer L. The decisive importance of cholesterol lowering therapy for coronary lesions and clinical course immediately after an acute coronary event: short and long term results of a controlled study. Circulation. 98:(Suppl. I):1998;1-45. Abstract.
19. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 99:1999;3227-3233.
20. Maas A.C., Green C.L., Shah S.A., et al. Incremental effects of anti-platelet, anti-thrombin and fibrinolytic therapy on the speed and stability of ST-segment recovery after acute MI. J. Am. Coll. Cardiol. 35:(Suppl. A):2000;372. Abstract.
21. Wallentin LC. Early cholesterol lowering treatment and early surgical intervention/balloon dilatation improves survival after myocardial infarction-landmark results from a large-scale Scandinavian register. Oral presentation at XXII Annual Congress of the European Society of Cardiology, Amsterdam, The Netherlands, August 26-30, 2000.
22. Schwartz G.G., Oliver M.F., Ezekowitz M.D., et al. Rationale and design of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study that evaluates atorvastin in unstable angina pectoris and in non-Q-wave myocardial infarction. Am. J. Cardiol. 81:1998;578-581.